

Felix Piecha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3727421/publications.pdf>

Version: 2024-02-01

18
papers

396
citations

840776

11
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

646
citing authors

#	ARTICLE	IF	CITATIONS
1	Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. <i>Journal of Hepatology</i> , 2018, 68, 1025-1032.	3.7	75
2	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	3.7	74
3	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E "The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020, 73, 696-699.	3.7	39
4	Arterial pressure suffices to increase liver stiffness. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G945-G953.	3.4	34
5	Rapid change of liver stiffness after variceal ligation and TIPS implantation. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G179-G187.	3.4	31
6	Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. <i>JHEP Reports</i> , 2019, 1, 90-98.	4.9	30
7	Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G484-G494.	3.4	29
8	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. <i>International Journal of Obesity</i> , 2021, 45, 2197-2204.	3.4	21
9	Treatment and re-treatment results of HCV patients in the DAA era. <i>PLoS ONE</i> , 2020, 15, e0232773.	2.5	16
10	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	2.0	12
11	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 "3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	4.4	12
12	Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?. <i>Hepatology Communications</i> , 2019, 3, 614-619.	4.3	4
13	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , 2020, 73, 1285-1287.	3.7	3
14	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	3.9	2
15	Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 840-848.	1.5	2
16	Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience. <i>PLoS ONE</i> , 2022, 17, e0265093.	2.5	1
17	Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study. <i>Hepatitis Monthly</i> , 2021, 21, .	0.2	0
18	Liver Stiffness Changes in Patients with Established Liver Cirrhosis. , 2020, , 599-603.		0